Cargando…
Erythrodermic psoriasis in post-coronavirus disease 2019 patient
Erythrodermic psoriasis (EP) is characterized by generalized erythema and desquamation affecting more than 75% of body surface area and usually accompanied by systemic symptoms. The triggers are medication withdrawal, drugs reactions, and systemic infections including coronavirus disease 2019 (COVID...
Autores principales: | Batubara, Irwan Saputra, Budianti, Windy Keumala |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asia Pacific Association of Allergy, Asthma and Clinical Immunology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066080/ https://www.ncbi.nlm.nih.gov/pubmed/35571549 http://dx.doi.org/10.5415/apallergy.2022.12.e16 |
Ejemplares similares
-
Erythrodermic Psoriasis Managed with Risankizumab
por: Alajlan, Abdulmajeed, et al.
Publicado: (2022) -
Erythrodermic psoriasis improved by Tildrakizumab
por: Trevisan, Giampaolo, et al.
Publicado: (2022) -
Erythrodermic Psoriasis Treated with Apremilast
por: Arcilla, John, et al.
Publicado: (2016) -
The Management of Erythrodermic Psoriasis Complicated by Cyclosporine
por: Rao, Suman, et al.
Publicado: (2020) -
Erythrodermic presentation of psoriasis in a patient treated with dupilumab
por: Tracey, Elisabeth H., et al.
Publicado: (2018)